Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite

Biostatistical Analysis, 3rd edn.

1996 • 1,319 citations

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

1993 • 652 citations

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

1990 • 451 citations

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

1994 • 429 citations

Noninvasive tests of CYP3A enzymes

1994 • 414 citations

A potentially hazardous interaction between erythromycin and midazolam

1993 • 352 citations

Pharmacokinetics of Haloperidol

1989 • 292 citations

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

1991 • 273 citations

Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology

1995 • 243 citations

Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles ofCYP2D6in a European Population

1991 • 224 citations

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes

1994 • 196 citations

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1992 • 190 citations

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

1984 • 185 citations

Polymorphic Drug Oxidation

1996 • 141 citations

Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype

1994 • 102 citations

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population

1996 • 98 citations

Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects

1995 • 96 citations

Debrisoquine oxidation phenotype during neuroleptic monotherapy

1991 • 66 citations

Sparteine oxidation is practically abolished in quinidine‐treated patients.

1986 • 64 citations

A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine

1994 • 59 citations

Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography

1989 • 53 citations

The influence of cigarette smoking on haloperidol pharmacokinetics

1990 • 46 citations

Use of Antisera in the Isolation of Human Specific Conjugates of Haloperidol

1989 • 43 citations

Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses

1981 • 38 citations

Blood Levels of Haloperidol in Schizophrenic Patients

1983 • 32 citations

Interaction between Erythromycin and the Benzodiazepines Diazepam and Flunitrazepam

1996 • 25 citations

Steady‐state serum kinetics of zotepine

1992 • 23 citations

Interaction between carbamazepine and bromperidol

1997 • 23 citations

Biotransformation of bromperidol in rat, dog, and man.

1983 • 23 citations

No Effect of the Anticholinergic Drugs Trihexyphenidyl and Biperiden on the Plasma Concentrations of Bromperidol and Its Reduced Metabolite

1997 • 13 citations